Leah Kuntz

New results for a study evaluating lumateperone.

Recent research evaluated evenamide as an add-on to an antipsychotic for patients with treatment-resistant schizophrenia.

We connected with a group working on the frontlines of Southern Turkey and Northern Syria to assist the survivors of the devastating earthquake.

The Future of Mental Health: Ketamine Therapy Report revealed that 55% of Americans who tried at home ketamine took more than the recommended dose.

Transcranial direct current stimulation for depression.

What are the available and upcoming AD treatments and how can you utilize them to best serve your patients?

A new, easy-to-use scale might be able to help clinicians determine the impact of tardive dyskinesia on patient functioning.

SPL026 with supportive therapy sees positive results in patients with major depressive disorder.

The FDA has accepted the NDA for nasal nalmefene, OPNT003, to treat opioid overdose.

Celebrating 25 years of Poetry of the Times with Richard Berlin, MD!

New approval for schizophrenia and bipolar I disorder.

How can you better provide care for American Indians and Alaska Natives?

The first phase 3 clinical trial of CTx-1301 for the treatment of ADHD has begun.

VR-based training may help improve social cognition and functioning in patients with schizophrenia.

Cariprazine is now FDA-approved as an adjunctive therapy to antidepressants.

What's the latest in dementia?

Cognitive and psychiatric symptoms at 3 months post-stroke might predict daytime sleepiness and fatigue at 12 months.

Check out the best clinical pearls from the 2022 Neuroscience Education Institute (NEI) Congress!

New research indicates worsened air quality leads to increased depressive symptoms in patients with bipolar disorder.

Screening for the symptom of worthlessness could save your adolescent patient’s life…

The first patient in a phase 2/3 study evaluating ulotaront for MDD has been enrolled.

New research finds that a urine test for formic acid could detect early-stage Alzheimer disease.

The phase 3 SERENITY III trial investigating at-home use of dexmedetomidine (BXCL501) sublingual film for agitation associated with bipolar I or II disorder or schizophrenia has started.

Have you missed the latest episodes of the series Tales From the Clinic: The Art of Psychiatry?

A new bill, the Breakthrough Therapies Act, would encourage the reclassification of MDMA and psilocybin from schedule I to schedule II drugs.

The second of a phase 3 study examining MDMA-AT just completed its final participant visit.

We may be one step closer to nonprescription naloxone.

ADHD is an all-day affair, and treating it in an adult population can be difficult.

What is the impact of antipsychotic side effects on medication adherence?